Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adverse Event Reporting System (FAERS) data were used to compare the association between different GLP-1RA and AKI in the real world. Methods: FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed. Results: We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively. Conclusions: Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients’ renal function regularly, especially for patients with high kidney risks such as obesity and age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmarket reports—which may overestimate side effects—have noted renal impairment upon initiation and dose escalation of GLP‐1s, which appears due to volume depletion resulting from dehydration caused by nausea and vomiting [123].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [123]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Concerns for acute kidney injury, however, have been raised among those with higher body weight (>99 kg) and older age (45–84 yrs).67”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [67]
In the citing paper
“Post-market reports—which may overestimate side effects—have noted renal impairment upon initiation and dose escalation of GLP-1s, possibly due to dehydration from nausea and vomiting [115].”
In the citing paper
“Postmarket reports—which may overestimate side effects—have noted renal impairment upon initiation and dose escalation of GLP-1s, which appears due to volume depletion resulting from dehydration caused by nausea and vomiting [123].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“A series of clinical trials, such as LEADER (5), SUSTAIN 6 (6), HARMONY (7), REWIND (8), and PIONEER 6 (9), proved that GLP-1RA could reduce the risk of cardiovascular events in addition to the effect of blood glucose reduction.”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“A series of clinical trials, such as LEADER (5), SUSTAIN 6 (6), HARMONY (7), REWIND (8), and PIONEER 6 (9), proved that GLP-1RA could reduce the risk of cardiovascular events in addition to the effect of blood glucose reduction.”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends
Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191028.001 · Cited by 3,130 · cited 1×
“48%), which may be related to the fact that the prevalence of type 2 diabetes mellitus in males is higher than that in female (31).”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“In addition, GLP-1RA, including liraglutide (10), dulaglutide (8), and exenatide (11), has shown renal benefits in clinical trials.”
BackgroundOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 1×
“A series of clinical trials, such as LEADER (5), SUSTAIN 6 (6), HARMONY (7), REWIND (8), and PIONEER 6 (9), proved that GLP-1RA could reduce the risk of cardiovascular events in addition to the effect of blood glucose reduction.”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253 · cited 1×
“In addition, GLP-1RA, including liraglutide (10), dulaglutide (8), and exenatide (11), has shown renal benefits in clinical trials.”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“The incretin effect is a phenomenon, which shows that the insulin response caused by oral glucose is much larger than that caused by intravenous glucose infusion (1, 2).”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“In this study, the adverse signals of exenatide, dulaglutide, and albiglutide in AKI were not found, but some studies have confirmed the close connection between exenatide and AKI (38), and dulaglutide is also considered to cause a decrease in body fluid intake (14), which may be one of the reasons for AKI (28).”
Renal Aging: Causes and Consequences
O’Sullivan, E. D., Hughes, J., & Ferenbach, D. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121308 · Cited by 484
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · cited 4×
“Therefore, the safety of this kind of drug needs longer clinical observation (14).”
BackgroundInfluentialLingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298
on behalf of the Feel4Diabetes-study Group, Kyrou, I., Tsigos, C., Mavrogianni, C., Cardon, G., Van Stappen, V., Latomme, J., Kivelä, J., Wikström, K., Tsochev, K., et al. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0463-3 · Cited by 286 · cited 1×
“An epidemiological study also supports this conclusion, and the prevalence of type 2 diabetes mellitus in different countries is mainly among middle-aged and elderly people (55-79 years old) (33).”
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s008 · Cited by 244
Drug-induced acute kidney injury: diverse mechanisms of tubular injury
Perazella, M. A. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000653 · Cited by 173
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144 · cited 2×
“When people eat, GLP-1 increases insulin secretion in response to glucose intake in the body and inhibits glucagon secretion of islet cells, resulting in a decrease in postprandial blood glucose levels (3).”
BackgroundPhysiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126 · cited 1×
“The incretin effect is a phenomenon, which shows that the insulin response caused by oral glucose is much larger than that caused by intravenous glucose infusion (1, 2).”
BackgroundExenatide-Associated Ischemic Renal Failure
Weise, W. J., Sivanandy, M. S., Block, C. A., & Comi, R. J. (2009) · Diabetes Care · doi:10.2337/dc08-1309 · Cited by 99 · cited 1×
“The results of several postmarketing studies have shown that AKI caused by exenatide is often unsatisfactory, with incomplete recovery of renal function or even renal failure (45).”
BackgroundHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99 · cited 1×
“GLP-1RA has played an increasingly important role in the treatment of diabetes (30).”
BackgroundEffects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97 · cited 3×
“Nearly 80 post-marketing reports of exenatide show that patients have acute renal failure or renal insufficiency after medication (18), and 95% of cases are accompanied by renal risk factors, including the use of nephrotoxic drugs, hypertension, heart failure, etc.”
BackgroundManagement of Obesity in Adults with CKD
Friedman, A. N., Kaplan, L. M., le Roux, C. W., & Schauer, P. R. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101472 · Cited by 94
Comparison of data mining methodologies using Japanese spontaneous reports
Kubota, K., Koide, D., & Hirai, T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.964 · Cited by 91 · cited 1×
“ROR and PRR have similar analysis principles and good consistency of results (39).”
BackgroundNetwork Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Zhao, M., Sun, S., Huang, Z., Wang, T., & Tang, H. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11220720 · Cited by 82 · cited 1×
“However, a meta-analysis on the clinical trial of new hypoglycemic drugs showed that the risk of AKI caused by GLP1RA was neutral and higher than that of another hypoglycemic drug, sodium-glucose co-transporter 2 inhibitor (SGLT2i) (27).”
BackgroundHow glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
DuMouchel, W., Smith, E. T., Beasley, R. W., Nelson, H. S., Yang, X., Fram, D. M., & Almenoff, J. S. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90181-6 · Cited by 63 · cited 1×
“BCPNN and MGPS have robust calculation results and strong ability to predict adverse reactions, but also have low sensitivity (41).”
BackgroundHou, Y., Ye, X., Gui-zhi, W., Cheng, G., Du, X., & He, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915938 · Cited by 63
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60 · cited 1×
“Current studies have shown that patients with pre-diabetes or type 2 diabetes mellitus often have defects in the effect of incretin, while exogenous GIP does not show a good insulinpromoting effect (4).”
BackgroundSide Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Seo, Y.-G. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20059 · Cited by 57 · cited 1×
“Post-marketing studies of liraglutide have confirmed that the increase in serum creatinine and AKI are mostly caused by nausea, vomiting, dehydration, or the combined use of renin-angiotensin-aldosterone system inhibitors (37).”
BackgroundDelaney, K. Z., & Santosa, S. (2022) · Obesity Reviews · doi:10.1111/obr.13393 · Cited by 56 · cited 1×
“Another study pointed out that due to gender differences, obese middle-aged men are more likely to develop insulin resistance and suffer from diabetes than women (32).”
BackgroundAcute Kidney Injury Associated With Semaglutide
Leehey, D. J., Rahman, M. A., Borys, E., Picken, M. M., & Clise, C. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.10.008 · Cited by 51 · cited 3×
“Frontiers in Endocrinology 06 events are accompanied by GLP-1RA, and not all cases can be attributed to prerenal problems (21, 28).”
BackgroundManagement of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 51 · cited 1×
“Despite these renal adverse outcomes, GLP-1RA is considered safe, including in patients with chronic kidney disease (22).”
BackgroundZhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4162 · Cited by 49
Kobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
Wang, C., Guo, X., Xu, J., Wu, C., Sun, Y., Ye, X., Qian, W., Ma, X., Du, W., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040561 · Cited by 36 · cited 1×
“Disproportionality analysis is the mainstream signal detection method in the world (26).”
Acute Interstitial Nephritis After Treatment With Liraglutide
Gariani, K., de Seigneux, S., & Moll, S. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.057 · Cited by 26 · cited 2×
“Although the hypothesis of indirect kidney injury is generally accepted, there are still unexplained acute kidney diseases, such as interstitial nephritis (20), which was also confirmed by semaglutide (21).”
BackgroundFunch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., et al. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s305496 · Cited by 24 · cited 1×
“Currently, most of the warning information about GLP-1RA comes from clinical trials or case reports, and only a limited number of pharmacovigilance studies have explored other adverse reactions of this kind of drug (23, 24).”
BackgroundFernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Cui, Y., Yang, Y., Lei, W., Lang, X., & Chen, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3826 · Cited by 17 · cited 1×
“Some studies have pointed out that drug-related AKI is associated with high mortality (44).”
BackgroundLiraglutide‐induced acute kidney injury
Narayana, S. K., Talab, S., & Elrishi, M. (2012) · Practical Diabetes · doi:10.1002/pdi.1727 · Cited by 15 · cited 1×
“At the beginning of the marketing of liraglutide and semaglutide, some cases also reported AKI (18, 19), interstitial nephritis, and acute tubular necrosis (20, 21).”
BackgroundAcute Kidney Injury Occurring in a Patient Initiated on Dulaglutide
Taylor, S. R., & Moody, M. T. (2018) · Journal of Pharmacy Technology · doi:10.1177/8755122518782155 · Cited by 11 · cited 3×
“Frontiers in Endocrinology 06 events are accompanied by GLP-1RA, and not all cases can be attributed to prerenal problems (21, 28).”
BackgroundRenal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
Vikulova, O. K., Zuraeva, Z. T., Michaleva, O. V., Nikankina, L. V., Шамхалова, М. Ш., Shestakova, M. V., & Dedov, I. I. (2018) · Terapevticheskii arkhiv · doi:10.26442/terarkh201890659-64 · Cited by 6 · cited 1×
“Another study on patients with type 1 diabetes showed that liraglutide could make positive changes in the levels of kidney sensitive biomarkers, and GLP-1RA may have a protective effect on patients with early renal damage in type 1 diabetes (17).”
Background
Research works printed but not linked: 1
- Jiawei Han, 2001, Data Ming concepts and techniques
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Post-market reports — which may overestimate side effects — have noted renal impairment upon initiation and dose escalation of GLP-1s, possibly due to dehydration from nausea and vomiting [115].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Post-market reports — which may overestimate side effects — have noted renal impairment upon initiation and dose escalation of GLP-1s, which appears due to volume depletion resulting from dehydration caused by nausea and vomiting [ 123].”
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“More serious but rare complications of the therapy include acute kidney failure [121] and gallbladder and biliary diseases [122].”
Metadata
- Authors
- Dong, S., & Sun, C.
- Affiliations
- Second Hospital of Tianjin Medical University (CN)
- Nanjing Children's Hospital (CN)
- Corresponding author
- Sun, Chuan
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2022-12-13
- Volume
- 13
- Pages
- 1032199-1032199
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9792852
- OpenAlex
- W4312138050
- Cited by
- 37
- References
- 44
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 10
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, acute kidney injury, liraglutide, drug-induced nephrotoxicity, pharmacovigilance, adverse drug reactions, obesity, renal function monitoring, drug safety
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Bayes Theorem, Female, Humans, Male, Middle Aged, Obesity, Acute Kidney Injury, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.